Watch ADCT. Know when insiders buy.
One email the day a filing lands. Free.
ADCT
ADC Therapeutics SA
1.36
+0.04 +3.03%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
6
FLAG · shorts 6
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $173.6MP/E —DIV YIELD —FCF YIELD -58.92%REV TTM $79.6M +3.0%NET INCOME −$96.9MNET CASH $212.9M52W 0.96 – 4.88SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $19.2M | +2.2% | — | −$25.4M | −$16.6M | — | -0.11 | −$11.8M | $0 | −$11.8M | Aug 13 |
| Q1 2026 · Mar 31 | $20.9M | −9.5% | — | −$25.2M | −$33M | — | -0.21 | −$29.7M | $32K | −$29.7M | May 4 |
| Q4 2025 · Dec 31derived | $23.1M | +36.4% | — | −$17.9M | −$6.4M | — | 0.02 | −$31.1M | $0 | −$31.1M | Mar 10 |
| Q3 2025 · Sep 30 | $16.4M | −11.0% | — | −$31M | −$41M | — | -0.30 | −$29.6M | $0 | −$29.6M | Nov 10 |
| Q2 2025 · Jun 30 | $18.8M | +8.2% | — | −$44.1M | −$56.6M | — | -0.50 | −$24.1M | $0 | −$24.1M | Aug 13 |
| Q1 2025 · Mar 31 | $23M | +27.6% | — | −$28.5M | −$38.6M | — | -0.36 | −$56.3M | $264K | −$56.6M | May 4 |
| Q4 2024 · Dec 31derived | $16.9M | +0.7% | — | −$32.4M | −$30.7M | — | -0.27 | −$21.9M | $90K | −$21.9M | Mar 10 |
| Q3 2024 · Sep 30 | $18.5M | +27.4% | — | −$35.6M | −$44M | — | -0.42 | −$25M | $216K | −$25.3M | Nov 10 |
| Q2 2024 · Jun 30 | $17.4M | — | — | −$29M | −$36.5M | — | -0.38 | −$32.8M | $30K | −$32.9M | Aug 12 |
| Q1 2024 · Mar 31 | $18.1M | — | — | −$33.6M | −$46.6M | — | -0.56 | −$44.1M | $531K | −$44.6M | May 14 |
| Q4 2023 · Dec 31derived | $16.8M | — | — | −$40M | −$85M | — | -1.04 | −$31.6M | $327K | −$32M | Mar 27 |
| Q3 2023 · Sep 30 | $14.5M | — | — | −$36.1M | −$46.7M | — | -0.57 | −$36.7M | $661K | −$37.3M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $81.4M | 92.9% | −$121.5M | −$142.6M | -175.3% | -1.12 | −$141.2M | $264K | −$141.4M | — | — |
| FY2024 · to Dec 31 | $70.8M | 91.6% | −$130.7M | −$157.8M | -222.8% | -1.62 | −$123.8M | $867K | −$124.7M | — | — |
| FY2023 · to Dec 31 | $69.6M | 96.4% | −$166M | −$240.1M | -345.1% | -2.94 | −$118.7M | $3.2M | −$121.9M | — | — |
| FY2022 · to Dec 31 | $209.9M | 98.4% | −$123.3M | −$157.1M | -74.9% | -2.01 | −$138.3M | $687K | −$139M | — | — |
Every number comes from ADC Therapeutics SA's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.